Macrocyclic Solid Forms for Farnesyltransferase Inhibitor Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers dependent on farnesylated proteins lack effective pharmaceutical formulations that can inhibit farnesyltransferase activity and target these proteins effectively.
Innovation Solution
Development of solid forms of macrocyclic compounds, their pharmaceutically acceptable salts and solvates, and pharmaceutical compositions, including methods for preparing tablets that incorporate these forms to inhibit farnesyltransferase activity and treat cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cancers dependent on farnesylated proteins, then treatment options are limited, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent develops multiple solid forms (polymorphs, solvates, salts) of farnesyltransferase inhibitor compounds, each with distinct crystal structures and physical properties. This allows optimization of therapeutic efficacy through selection of specific solid forms while maintaining the core chemical structure necessary for farnesyltransferase inhibition.
Solution Approach 2:
The patent creates pharmaceutical compositions that combine farnesyltransferase inhibitor compounds with pharmaceutically acceptable excipients, carriers, and formulation agents. These composite formulations enhance delivery, stability, and bioavailability of the active compounds, providing effective treatment options for cancers dependent on farnesylated proteins.
2Ease of manufacture
If solid forms of macrocyclic compounds are developed, then pharmaceutical formulations can be created, but formulation complexity increases
Solution Approach 1:
The patent separates the active pharmaceutical ingredient (farnesyltransferase inhibitor) from excipients and formulation components, allowing independent characterization and optimization of each element. This segmentation enables systematic development of solid forms and formulations through controlled variables approach.
Solution Approach 2:
The patent employs pharmaceutically acceptable excipients, carriers, and processing aids as intermediaries to facilitate the formulation of farnesyltransferase inhibitors. These intermediaries bridge the gap between the active compound and the final dosage form, simplifying the formulation process while maintaining manufacturability.
3Manufacturing precision
If de-lumping and blending steps are incorporated in tablet preparation, then mixture homogeneity is improved, but manufacturing time increases
Solution Approach 1:
The patent performs de-lumping of solid forms prior to blending with excipients, preventing aggregate formation during subsequent processing steps. This preliminary action ensures uniform distribution of the active ingredient throughout the formulation, achieving homogeneous mixing in a single blending operation rather than requiring multiple cycles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid forms and compositions provide therapeutic efficacy in inhibiting farnesyltransferase, thereby offering a potential treatment for cancers dependent on farnesylated proteins.
Implementation Method 1
one of the two diastereomeric salts precipitates selectively from the solvent and the other of the two diastereomeric salts is selectively soluble in the solvent
Data Source
AI summary
The present disclosure relates to solid forms of Compound 1, or a pharmaceutically acceptable form thereof, a pharmaceutically acceptable salt of Compound 1, or pharmaceutically acceptable solvate thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating cancer dependent on a farnesylated protein, using the same.